IB-01212: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11520915 |
| CHEMBL ID | 504208 |
| MeSH ID | M0509469 |
| Synonym |
|---|
| CHEMBL504208 |
| ib-01212 |
| n(me2)leu-ser(1)-n(me)leu-n(me)phe-(2).n(me2)leu-ser(2)-n(me)leu-n(me)phe-(1) |
| (2s)-n-[(3s,6s,9s,13s,16s,19s)-3,13-dibenzyl-19-[[(2s)-2-(dimethylamino)-4-methylpentanoyl]amino]-4,7,14,17-tetramethyl-6,16-bis(2-methylpropyl)-2,5,8,12,15,18-hexaoxo-1,11-dioxa-4,7,14,17-tetrazacycloicos-9-yl]-2-(dimethylamino)-4-methylpentanamide |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID407720 | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Design and synthesis of FAJANU: a de novo C(2) symmetric cyclopeptide family. |
| AID407721 | Cytotoxicity against human A549 cells after 72 hrs by SRB assay | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Design and synthesis of FAJANU: a de novo C(2) symmetric cyclopeptide family. |
| AID407722 | Cytotoxicity against human HT29 cells after 72 hrs by SRB assay | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Design and synthesis of FAJANU: a de novo C(2) symmetric cyclopeptide family. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||